IMMU:NSD-Immunomedics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.94

Change

0.00 (0.00)%

Market Cap

USD 20.31B

Volume

0.24M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A

ETFs Containing IMMU

Symbol Name Weight Mer Price(Change) Market Cap
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+2.26%)

USD0.34B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

+15.00 (+2.08%)

USD2.13B
WLDS:LSE iShares III plc - iShares.. 0.00 % 0.00 %

+0.07 (+1.29%)

USD3.95B
WOSC:LSE SPDR MSCI World Small Cap.. 0.00 % 0.45 %

+0.83 (+1.14%)

USD0.43B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -59.37% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.37% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 177.48% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.48% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 102.28% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.28% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 137.90% N/A N/A 8% F
Risk Adjusted Return 74.17% N/A N/A 90% A-
Market Capitalization 20.31B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.23 N/A N/A N/A N/A
Price / Cash Flow Ratio -91.30 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -80.14% N/A N/A N/A N/A
Return on Assets -25.16% N/A N/A N/A N/A
Debt to Equity Ratio 96.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.15 N/A N/A N/A N/A
Short Percent 8.66% N/A N/A N/A N/A
Beta 2.90 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.